Nutritional Supplement Ocoxin<sup>®</sup> Combined with Oxaliplatin-Based Chemotherapy in Patients with Metastatic Colorectal Cancer

Background: Advanced colorectal cancer (CRC) is associated with significant morbidity, which, combined with the adverse effects of cancer treatment, can further impair patient quality of life. The primary objective was to evaluate the impact of Ocoxin oral solution (OOS) in combination with oxaliplatin-based chemotherapy on quality of life. Methods: Forty patients participated in an exploratory, prospective, multicentre clinical trial at the “Hermanos Ameijeiras” University Hospital and the National Institute of Oncology in Havana, Cuba. Quality of life was measured using the EORTC QLQ-C30 and EORTC QLQ-C29 questionnaires. Toxicity was assessed using the NCI-CTC-AE classification, version 4.0. Results: Scores remained stable over time for global quality of life and functional scale criteria, while, regarding symptoms, a reduction in pain perception and loss of appetite was observed at three months. The number and severity of adverse events were lower (4.2% grade 3 - 4) than those reported with this type of chemotherapy. No adverse events (AEs) related to OOS were recorded. Biochemical and nutritional parameters remained stable during treatment. Conclusions: This clinical study is the first report on the use of OOS in patients with metastatic colon cancer, maintaining optimal quality of life and reducing the intensity of chemotherapy toxicity.